Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report released on Thursday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald raised their price target on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st.

Vanda Pharmaceuticals Stock Performance

VNDA opened at $4.52 on Thursday. The stock’s 50 day moving average price is $4.91 and its 200-day moving average price is $5.22. Vanda Pharmaceuticals has a one year low of $3.30 and a one year high of $6.75. The stock has a market cap of $263.47 million, a price-to-earnings ratio of -23.79 and a beta of 0.77.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. The business had revenue of $50.47 million during the quarter. As a group, analysts predict that Vanda Pharmaceuticals will post -0.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets grew its position in shares of Vanda Pharmaceuticals by 70.1% during the 1st quarter. BNP Paribas Financial Markets now owns 101,363 shares of the biopharmaceutical company’s stock worth $417,000 after buying an additional 41,767 shares in the last quarter. Schulhoff & Co. Inc. purchased a new position in Vanda Pharmaceuticals during the 1st quarter valued at about $158,000. Empowered Funds LLC increased its position in Vanda Pharmaceuticals by 8.2% during the 1st quarter. Empowered Funds LLC now owns 201,283 shares of the biopharmaceutical company’s stock valued at $827,000 after purchasing an additional 15,215 shares during the period. Susquehanna Fundamental Investments LLC bought a new stake in shares of Vanda Pharmaceuticals in the 1st quarter valued at about $1,158,000. Finally, Sei Investments Co. lifted its position in shares of Vanda Pharmaceuticals by 39.6% in the 1st quarter. Sei Investments Co. now owns 518,851 shares of the biopharmaceutical company’s stock worth $2,132,000 after purchasing an additional 147,066 shares during the period. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.